1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 2002;20(5):1248-1259.
2. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol .2007;197(6):676.
3. Vergote I, Trope CG, Amant F, et al. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. N Engl J Med. 2010;363(10):943-53.
4. Kehoe S, Hook J, Nankivell M, et al. chemotherapy or upfront surgery for newly whose syndromes we were partly certain advanced ovarian: results from the MRC touch trial. ASCO Unv. 2013.
5. Peiretti M, Zanagnolo V, Aletti GD, et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 2010;119(2):259-264.
6. van Meurs HS, Tajik P, Hof MH, et al. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in IIIC or stage IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Reatment of Cancer 55971 randomised trial. Eur J Cancer. 2013;49(15):3191-3201.
7. Tozzi R, Giannice R, Cianci S, et al. Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecol Oncol. 2015;138(2):252-258.
8. Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124(1):10-14.
9. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2:2-3.
10. Neil S. Horowitz, Austin Miller, Bunja Rungruang, et al. Does Aggressive Surgery Improve Outcomes? Interaction between Preoperative Disease Burden and Complex Surgery in Patients with Advanced-Stage Ovarian Cancer: An Analysis of GOG 182. J Clinc Oncol. 2015;33(8)937-943.
11. Rodriguez N, Miller A, Richard SD, et al. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: An analysis of Gynecologic Oncology Group (GOG) 182. Gynecol Oncol. 2013;130(3):487-492.
12. Bristow RE, Duska LR, Lambrou NC, et al. A model for predicting surgical outcome in patient with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89(7):1532-1540.
13. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90(2):390-396.
14. Aletti GD, Santillan A, Eisenhauer EL, et al. A new frontier for quality of care in gynecologiconcology surgery: multi-institutional assessment of short-term out comes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107(1):99-106.
15. Fagotti A, Fanfani F, Ludovisi M, et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol. 2005;96(3):729-735.
16. Brun JL, Rouzier R, Uzan S, Darai E. External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecol Oncol. 2008;110(3):354-359.
17. Chereau E, Lavoue V, Ballester M, et al. External validation of a laparoscopic-based score to evaluate resectability for patients with advanced ovarian cancer undergoing interval debulking surgery. Anticancer Res. 2011;31(12):4469-4474.
18. Fagotti A, Fanfani F, Vizzielli G, et al. Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery? Gynecol Oncol. 2010;116(1):72-77.
19. Fagotti A, Vizzielli G, Fanfani F, et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol Oncol. 2013;131(2):341-346.
20. Fanfani F, Fagotti A, Gallotta V, et al. Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery. Gynecol Oncol. 2010;116(3):497-501.
21. Petrillo M, Vizzielli G, Fanfani F, et al. Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelialovarian: proof of a concept. Gynecol Oncol. 2015;139(1):5-9.
22. Gerestein CG, Nieuwenhuyzen-de Boer GM, Eijkemans MJ, Kooi GS, Burger CW. Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer. 2010;46(1):102-109.
23. Peiretti M, Zanagnolo V, Aletti GD, et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncologic outcomes-Single institution experience. Gynecol Oncol. 2010;119(2):259-264.
24. Chi DS, Zivanovic O, Levinson KL, et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol. 2010;119(1):38-42.
25. Vizzielli G, Costantini B, Tortorella L, et al. Influence of intraperitoneal promotes assessed by laparoscopy on prognosis of advanced ovarian: an exploratory analysis of a single-institution experience. Ann surg Oncol. 2014;21(12):3970-3977.
26. Tucker SL, Gharpure K, Herbrich SM, et al. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res. 2014;20(12):3280-3288.
27. Suidan RS, Ramirez PT, Sarasohn DM, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014;134(3):468-472.